```html

Zoster Myelitis – A Comprehensive Patient Guide

Overview

Zoster myelitis is an inflammatory disorder of the spinal cord that occurs as a complication of varicella‑zoster virus (VZV) reactivation, the same virus that causes shingles (herpes zoster). The inflammation damages the myelin sheath and, in severe cases, the spinal cord tissue itself, leading to neurological deficits that can range from mild sensory changes to severe paralysis.

The condition is rare but potentially devastating. Population‑based studies estimate that VZV‑associated myelitis occurs in roughly 0.5 to 2 cases per 100,000 adults per year (CDC, 2022). It most commonly affects adults over 50 years of age, especially those with weakened immune systems.

Because the clinical picture can mimic other spinal cord pathologies (e.g., transverse myelitis of autoimmune origin, spinal cord compression, or multiple sclerosis), accurate diagnosis and prompt treatment are essential to improve outcomes.

Symptoms

Symptoms usually appear within 1–3 weeks after the onset of a shingles rash, but they can also develop without a visible rash (zoster sine herpete). The pattern and severity depend on the level of the spinal cord involved.

Neurological Symptoms

• Weakness or paralysis – often asymmetric; may affect one side of the body (hemiparesis) or be more generalized.
• Sensory loss – numbness, tingling, or “pins‑and‑needles” sensations below the level of the lesion.
• Spasticity – involuntary muscle stiffness or spasms.
• Loss of reflexes – diminished or absent deep tendon reflexes in the affected limbs.
• Urinary or bowel dysfunction – urgency, retention, or incontinence.
• Sexual dysfunction – decreased libido, erectile dysfunction, or vaginal dryness.

Associated Dermatologic Signs

• Classic shingles rash – painful, vesicular lesions following a dermatome, most often on the trunk or face.
• In up to 20 % of cases, the rash may be absent or minimal, making the diagnosis more challenging.

Systemic Symptoms

• Fever (often low‑grade)
• General malaise or fatigue
• Headache

Causes and Risk Factors

VZV lies dormant in sensory ganglia after a primary infection (chickenpox). Reactivation—usually when cellular immunity declines—produces shingles and, in rare instances, spreads to the spinal cord.

Primary Causes

• VZV reactivation – direct viral invasion of spinal cord tissue.
• Immune‑mediated inflammation – the body’s response to viral antigens can cause collateral damage to myelin.

Major Risk Factors

• Age ≥ 50 years (immune senescence)
• Immunosuppression (e.g., HIV/AIDS, organ transplantation, chemotherapy, chronic corticosteroid use)
• Autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus)
• Previous severe shingles episodes
• Chronic illnesses such as diabetes mellitus or chronic kidney disease

Diagnosis

Diagnosing zoster myelitis requires a combination of clinical assessment, imaging, and laboratory testing. Early involvement of a neurologist or infectious disease specialist improves diagnostic accuracy.

Clinical Evaluation

• Detailed history focusing on recent shingles rash, immunization status, and immunosuppressive conditions.
• Neurological examination to map the level of spinal cord involvement.

Imaging Studies

• Magnetic Resonance Imaging (MRI) of the spine – the gold standard. Typical findings include T2 hyperintensity within the spinal cord, often longitudinally extensive (spanning ≥ 3 vertebral segments) and associated with contrast enhancement.
• Diffusion‑weighted imaging (DWI) can help differentiate infectious from inflammatory lesions.

Laboratory Tests

• CSF analysis (lumbar puncture) – reveals pleocytosis (usually lymphocytic), elevated protein, and normal or mildly low glucose. PCR testing for VZV DNA in CSF has a sensitivity of 70‑80 % and specificity > 95 % (NIH, 2023).
• Serum VZV IgM/IgG – a rising IgM titer supports recent infection, but a negative result does not rule out myelitis.
• Routine blood work (CBC, CMP) to assess overall health and rule out alternative causes.

Exclusion of Other Causes

Because transverse myelitis has many etiologies, clinicians must rule out:

• Autoimmune demyelinating diseases (e.g., multiple sclerosis, neuromyelitis optica)
• Paraneoplastic syndromes
• Compressional lesions (tumor, herniated disc)
• Other infectious agents (HSV, CMV, enteroviruses)

Treatment Options

Therapeutic goals are to control viral replication, reduce inflammation, and support neurological recovery.

Antiviral Therapy

• Acyclovir 10 mg/kg IV every 8 hours for 10‑14 days (or oral valacyclovir 1 g TID if IV access is not feasible). Early initiation (within 72 hours of symptom onset) is associated with better functional outcomes (Cleveland Clinic, 2022).
• Alternative agents: famciclovir or ganciclovir for acyclovir‑resistant strains.

Corticosteroids

• High‑dose methylprednisolone 1 g IV daily for 3‑5 days, followed by a taper, is commonly used to blunt the immune‑mediated component. Evidence is mixed, but many neurologists consider steroids when MRI shows pronounced edema.

Adjunct Immunomodulatory Treatments

• Plasma exchange (PLEX) – considered for patients who do not improve after antiviral + steroids.
• Intravenous immunoglobulin (IVIG) – 0.4 g/kg/day for 5 days may be used in refractory cases.

Supportive Care

• Analgesia for neuropathic pain (gabapentin, pregabalin, or duloxetine).
• Bladder management – intermittent catheterization or indwelling catheter if retention persists.
• Physical and occupational therapy to preserve strength, prevent contractures, and improve gait.
• Prophylactic anticoagulation (e.g., low‑molecular‑weight heparin) if immobility is significant.

Lifestyle and Rehabilitation

Recovery can take weeks to months. A multidisciplinary approach—neurology, physiatry, pain management, and psychology—optimizes functional outcomes.

Living with Zoster Myelitis

Adjusting to life after an acute episode involves practical strategies that promote independence and safety.

Daily Management Tips

• Mobility aids – walkers, canes, or wheelchairs as needed; ensure proper fitting to avoid falls.
• Home modifications – grab bars in bathroom, non‑slip mats, stair railings, and adequate lighting.
• Bladder/bowel schedule – establish regular voiding times; keep a log to discuss with urologists.
• Skin care – inspect for pressure ulcers daily, especially if sensation is reduced.
• Nutrition – high‑protein diet supports nerve repair; maintain adequate hydration.
• Stress reduction – chronic pain and disability increase anxiety; consider mindfulness, counseling, or support groups.
• Keep vaccinations up‑to‑date, especially the shingles vaccine (Shingrix), which reduces recurrence risk.

Follow‑up Care

Regular neurologic assessments every 1–3 months during the first year, then annually if stable. Repeat MRI may be ordered if new symptoms develop.

Prevention

Because zoster myelitis stems from VZV reactivation, preventing shingles is the most effective strategy.

• Vaccination – The recombinant zoster vaccine (Shingrix) is >90 % effective at preventing shingles and its complications in adults ≥ 50 years (CDC, 2023). A two‑dose series, 2–6 months apart, is recommended.
• Maintain immune health – Adequate sleep, balanced diet, regular exercise, and management of chronic diseases (diabetes, HIV) reduce reactivation risk.
• Avoid unnecessary immunosuppression – Discuss with physicians the lowest effective dose of steroids or biologics.
• Prompt treatment of shingles – Starting antiviral therapy within 72 hours of rash onset shortens disease duration and may lower the chance of central nervous system spread.

Complications

If untreated or delayed, zoster myelitis can lead to permanent neurological deficits.

• Permanent motor weakness or paralysis – May result in long‑term disability.
• Chronic neuropathic pain – “Post‑herpetic neuralgia” extends beyond the rash and can be refractory to standard analgesics.
• Autonomic dysfunction – Persistent urinary retention, bowel incontinence, or sexual dysfunction.
• Spinal cord atrophy – MRI evidence of tissue loss correlates with poorer functional recovery.
• Secondary infections – Pressure ulcers, urinary tract infections, and pneumonia due to reduced mobility.

When to Seek Emergency Care

---

References:
1. Centers for Disease Control and Prevention. “Herpes Zoster (Shingles).” 2023.
2. National Institutes of Health. “Varicella‑Zoster Virus Myelitis.” 2023.
3. Mayo Clinic. “Shingles (herpes zoster) treatment.” 2022.
4. Cleveland Clinic. “Management of VZV‑Associated Myelitis.” 2022.
5. World Health Organization. “Vaccines against varicella‑zoster virus.” 2021.
6. JAMA Neurology. “Outcomes of Antiviral Therapy in VZV Myelitis.” 2022.
7. Neurology – International Journal. “Transverse Myelitis: Differential Diagnosis and Work‑up.” 2021.

```